GlassScriptPhysician profile
Lindsey Rawlins
NPI 1447741475
$1,083.66
in general payments reported to CMS, 2019-2025
10 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $158 · 2023: $153 · 2024: $245 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $340.61 | 2021-2025 | Apligraf, Puraply Wound Matrix, Affinity |
| Smith+Nephew, INC. | $190.04 | 2021-2025 | Grafix Pl, Pico 7, Grafix |
| Kerecis Limited | $132.87 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Augmedics INC. | $109.40 | 2022-2024 | Xvision |
| Kci USA, INC. | $96.79 | 2021-2023 | Promogran Prisma, Activ.A.C. |
| Solventum Corporation | $75.89 | 2024-2025 | Activ.A.C., 3m Coban |
| Integra Lifesciences Corporation | $45.98 | 2021 | |
| Bsn Medical INC | $39.16 | 2025 | |
| Acera Surgical, INC. | $29.25 | 2022 | |
| Reprise Biomedical, INC. | $23.67 | 2024 | Mirotract, Miro3d Fibers, Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Rawlins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.